Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.42 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1846608 | 0.83 | BRAF (0.51) | BRAFLMNAL3MBTL1SGK1 | |
| SCHEMBL1846520 | 0.83 | BRAF (0.52) | BRAFLMNAL3MBTL1SGK1NR1I2 | |
| SCHEMBL10272379 | 0.81 | LMNA (0.41) | BRAFLMNAL3MBTL1SGK1HTR1A | |
| SCHEMBL1848600 | 0.81 | BRAF (0.65) | BRAFLMNAL3MBTL1SGK1NR1I2 | |
| SCHEMBL1850142 | 0.78 | BRAF (0.48) | BRAFLMNAL3MBTL1SGK1BRD4 | |
| SCHEMBL1847962 | 0.77 | BRAF (0.49) | BRAFLMNAL3MBTL1SGK1 | |
| SCHEMBL1851463 | 0.75 | PIK3C3 (0.59) | BRAF | |
| SCHEMBL1848152 | 0.74 | L3MBTL1 (0.48) | BRAFLMNAL3MBTL1SGK1 | |
| SCHEMBL12417937 | 0.74 | BRAF (0.70) | BRAFNR1I2 | |
| SCHEMBL1847748 | 0.73 | LRRK2 (0.45) | BRAFLMNAL3MBTL1SGK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-8946250-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-02-03 | — | — | US | disclosed |
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-01-02 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| US-8541575-B2 | 3,4-diarylpyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-24 | — | — | US | disclosed |
| EP-2324008-B1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2012-05-09 | — | — | EP | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-16 | — | — | US | disclosed |
| EP-2324008-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010010154-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005150-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | BRAF 115/4885RET 360/4885LMNA 3734/4885 |
| US-20110144068-A1 | 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K3, MAP3K19, MAP3K15 | BRAF 115/4885RET 360/4885LMNA 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.